FDA Approves Longer-Acting Calaspargase Pegol-mknl for ALL

The FDA approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC) as a component of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients 1 month to 21 years of age.